Oxford BioMedica Sign Agreement with Mayo Clinic

UK company Oxford BioMedica announced today that they have linked up with the USA’s renowned Mayo Clinic to develop a novel gene therapy for the treatment of chronic glaucoma. Under the agreement, the companies will undertake pre-clinical studies to establish the feasibility of treating glaucoma using Oxford BioMedica’s LentiVector gene delivery technology expressing a COX-2

Continue Reading